8-K: Phio Pharmaceuticals' Skin Cancer Study Advances to Fourth Dose Cohort Following Positive Safety Review

Phio Pharmaceuticals announces its INTASYL PH-762 skin cancer study will advance to the fourth dose escalation cohort after a positive recommendation from the Safety Monitoring Committee.

Summary

• Phio Pharmaceuticals Corp. announced that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer.
• The Phase 1b trial is a multi-center, dose-escalating trial evaluating the safety and tolerability of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
• In the third cohort, three patients with cutaneous squamous cell carcinoma were enrolled, and injections were well tolerated with no serious adverse events or dose-limiting toxicities.
• Pathology results related to the efficacy of PH-762 in the third cohort are forthcoming.
• Previously, in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance) at Day 36.
• All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.

Sentiment

Score: 7

Explanation: The document presents a positive outlook due to the advancement of the clinical trial and promising early results, but it also acknowledges the inherent risks and uncertainties associated with drug development.

Positives

• The Safety Monitoring Committee recommended dose escalation for PH-762, indicating a positive safety profile.
• The third cohort demonstrated that PH-762 was well tolerated with no serious adverse events or dose-limiting toxicities.
• The second cohort showed promising efficacy results, with two patients achieving complete tumor clearance and one patient achieving significant partial clearance.
• The company is optimistic about PH-762 as a potential non-surgical treatment for skin cancers.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those indicated in the forward-looking statements due to various factors, including the development of product candidates, clinical trial results, and the ability to obtain future financing.
• The company's ability to commercialize product candidates depends on regulatory filings and approvals.

Future Outlook

The company plans to continue the Phase 1b clinical trial, evaluating the safety, tolerability, and efficacy of PH-762 in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with the goal of determining the recommended dose for further study.

Management Comments

• Mary Spellman, MD, Phio's acting Chief Medical Officer, stated that they are impressed with the continuing safety profile of PH-762.
• Robert Bitterman, President and CEO of Phio Pharmaceuticals, is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Industry Context

The development of PH-762 as a potential non-surgical treatment for skin cancer aligns with the industry's ongoing efforts to develop less invasive and more targeted therapies for cancer. siRNA-based therapeutics represent a promising approach to gene silencing and immune modulation in oncology.

Comparison to Industry Standards

• Companies like Alnylam Pharmaceuticals are pioneering siRNA therapeutics, but Phio's focus on intratumoral delivery for skin cancer offers a unique approach.
• The complete and partial response rates observed in the second cohort of Phio's trial are encouraging compared to standard treatments like surgery and radiation, but further data is needed to establish PH-762's efficacy relative to other emerging therapies like immune checkpoint inhibitors.

Stakeholder Impact

• Shareholders may react positively to the news of the clinical trial's progress and the potential for PH-762 to become a non-surgical treatment for skin cancer.
• Patients with skin cancer may benefit from the development of a new treatment option.
• Employees of Phio Pharmaceuticals may be motivated by the progress of the company's lead clinical program.

Next Steps

• Advance INTASYL PH-762 to a fourth dose escalation cohort.
• Continue the Phase 1b clinical trial to evaluate the safety, tolerability, and efficacy of PH-762.
• Assess the tumor response and determine the recommended dose for further study of PH-762.
• Await pathology results related to the efficacy of PH-762 in the third cohort.

Key Dates

Keywords

PH-762, INTASYL, siRNA, skin cancer, clinical trial, dose escalation, Phio Pharmaceuticals, Safety Monitoring Committee, cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma